Breast cancer that has spread to lymph nodes may be treated more aggressively than localized cancer, because it has a greater potential to travel to other parts of the body. You have thousands of ...

Apr. 4, 2025 — A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated ...

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a malignancy where the first-generation drug ibrutinib (Imbruvica ...

Having too many or too few lymphocytes may be a sign of an acute or chronic infection or a sign of a severe disease, such as lymphoma, lupus, or leukemia. Lymphocytes are a type of leukocyte (white ...

Among some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, treatment with the bispecific antibody odronextamab has been associated ...

Non-Hodgkin lymphoma is a cancer that affects lymphocytes, a type of white blood cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade ...

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago. The US regulator ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...

Medics took a biopsy of the growth and found it was Hodgkin lymphoma - a deadly type of blood cancer. Around 2,100 people are diagnosed with Hodgkin lymphoma in the UK each year. It is an uncommon ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...